Livingston, N.J.-based Reprogenetics offers pre-implantation genetic screening and diagnosis for in vitro fertilization, Cooper said. The $46.5 million deal isn’t expected to affect earnings per share this year or in 2016, but should be accretive thereafter, the company said.
Reprogenetics put up sales of roughly $20 million during the 12 months ended July 31, Cooper said. Low-double-digit growth is forecast for the coming years, according to a press release.
“The acquisition of Reprogenetics strengthens our industry-leading IVF business by positioning us at the forefront of the emerging field of genetic testing targeted to improving IVF pregnancy rates while helping to eliminate severe genetic disorders,” president & CEO Robert Weiss said in prepared remarks.
Cooper is based in Pleasanton, Calif.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.